Showing results (241-250 of 496) with videos related to
Sort By:
Pageof 50
European Journal of Cancer (Oxford, England : 1990)|July 13, 2026
Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysisGuanqiao Li, Yiwen Pu, Congzhou Chen, et al.Circulation. Cardiovascular Quality and Outcomes|June 15, 2017
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein InhibitorsSpencer Phillips Hey, Jessica M Franklin, Jerry Avorn, et al.American Heart Journal|December 28, 2020
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort studyBenjamin N Rome, Joshua J Gagne, Jerry Avorn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2022
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny LabelingBryan S Walsh, Aaron S Kesselheim, Ameet Sarpatwari, et al.Nature Biomedical Engineering|June 29, 2019
Review times and adverse events for cardiovascular devicesAriel Dora Stern, Daniel B Kramer, Melissa Ouellet, et al.BMJ (Clinical Research Ed.)|June 30, 2016
Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort studyThomas J Hwang, Elisaveta Sokolov, Jessica M Franklin, et al.Health Affairs (Project Hope)|October 8, 2014
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugsAaron S Kesselheim, Yongtian Tina Tan, Jonathan J Darrow, et al.Pediatrics|June 9, 2026
Use of Leucovorin After the FDA Announcement of Its Use for Autism Spectrum DisordersBenjamin N Rome, John Kim, Jose F Figueroa, et al.Health Affairs (Project Hope)|May 1, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously EstimatedFrazer A Tessema, Rachel E Barenie, Jerry Avorn, et al.The Milbank Quarterly|September 18, 2024
A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key StakeholdersIselin Dahlen Syversen, Kevin Schulman, Aaron S Kesselheim, et al.Pageof 50